To identify and characterize the molecules regulating the functions of the immune system or to reach and manipulate these targets, monoclonal antibodies are tools with undisputed precision. To conduct its research programs, in-house or through partnerships with academic institutes, clinical research units, biopharmaceutical or diagnostic companies, the CIML has created in 2006, under the leadership of Michel Pierres, a platform dedicated exclusively to the design and production of monoclonal antibodies.

This plaform was the prefiguration of  MI-mAbs, an innovative immunotechnology center established in 2011 by Aix-Marseille Université (AMU) and its private subsidiary Protisvalor, CNRS, Inserm, the Institut Paoli-Calmettes (IPC), 3 of their research centers (the Centre d’Immunologie de Marseille-Luminy, the Cancer Research Center of Marseille and the Centre for Immunophenomics), Innate Pharma and Sanofi. At the interface of "therapeutic targets discoverers” from research and developers of the biopharmaceutical industry, Mi-mAbs helps to make the Marseille metropolis a world leader in research and development of immune-based therapies, and first and foremost for immunotherapy antibodies.

MI-mAbs Web site